> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Vyzulta for Intraocular Pressure
- URL: https://www.fdaweb.com/fda-approves-vyzulta-for-intraocular-pressure/
- Published: 2017-11-02T12:00:00.000Z
- Updated: 2026-09-14T22:59:38.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5140042

FDA has approved a Bausch + Lomb and Nicox NDA for Vyzulta (latanoprostene bunod ophthalmic solution, 0.024%), indicated for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The once daily therapy has a dual mechanism of action, according to the company, and works by metabolizing into two moieties, latanoprost acid, which primarily works within the uveoscleral pathway to increase aqueous humor outflow, and butanediol mononitrate, which releases nitric oxide to increase outflow through the trabecular meshwork and Schlemm’s canal. The most common ocular adverse events include conjunctival hyperemia, eye irritation, eye pain and instillation site pain.